Stephen Welch is the Chief Financial Officer of Mallinckrodt’s Specialty Generics segment and also serves as the Chief Transformation Officer for Mallinckrodt Pharmaceuticals. He served as the company’s first day declarant in the chapter 11 case and has responsibility for the ongoing restructuring process. Mr. Welch is a member of Mallinckrodt’s Executive Leadership Team and serves on the boards of the Specialty Generics entities.
Mr. Welch has over 20 years of experience in corporate finance and tax matters, including nearly 15 years of experience in the pharmaceuticals industry. He’s an established leader with demonstrated ability to shape and execute strategy to drive results and create value.
Mr. Welch joined Mallinckrodt in 2012 and during his time with the company has held a number of strategic roles within the company including Vice President of Corporate Strategy and Chief of Staff to the president & CEO. He began his time at Mallinckrodt in the Tax Department, focused primarily on M&A transactions and business integrations.
Prior to joining Mallinckrodt, Mr. Welch was head of the tax departments at Human Genome Sciences and PharMerica. He began his career at PricewaterhouseCoopers.
Mr. Welch holds a Juris Doctor degree from the Georgetown University Law Center and a bachelor’s degree in Political Science from the California State University, Bakersfield. He is member of the California Bar.